New Radiation-Chemo cocktail aims to boost stem cell transplant success in tough leukemias
NCT ID NCT03494569
First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times
Summary
This phase 1 trial is testing a combination of total marrow and lymphoid irradiation (TMLI) plus two chemotherapy drugs, fludarabine and melphalan, given before a donor stem cell transplant. The goal is to find the safest dose of radiation that can kill cancer cells while preparing the body for new donor stem cells. The study includes 36 people with high-risk acute leukemia or myelodysplastic syndrome. Researchers are closely watching for side effects to see if this approach is tolerable and could lead to better outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fludarabine, melphalan, and total marrow and lymphoid irradiation
- What this could lead to
- If successful, this could improve the safety and effectiveness of stem cell transplants for people with hard-to-treat leukemia or myelodysplastic syndrome.
- What could go wrong
- This is an early phase 1 trial with only 36 participants, so results may not apply broadly. The treatment involves strong chemo and radiation, which can cause serious side effects like organ damage or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?